Bannaga A, Arasaradnam RP. Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review. World J Gastroenterol 2020; 26(33): 5022-5049 [PMID: 32952347 DOI: 10.3748/wjg.v26.i33.5022]
Corresponding Author of This Article
Ayman Bannaga, MBBS, MRCP, Research Fellow, Department of Gastroenterology and Hepatology, University Hospital Coventry and Warwickshire NHS Trust, Clifford Bridge Road, Coventry CV2 2DX, West Midlands, United Kingdom. aymanbannaga@yahoo.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 7, 2020; 26(33): 5022-5049 Published online Sep 7, 2020. doi: 10.3748/wjg.v26.i33.5022
Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review
Ayman Bannaga, Ramesh P Arasaradnam
Ayman Bannaga, Ramesh P Arasaradnam, Department of Gastroenterology and Hepatology, University Hospital Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, West Midlands, United Kingdom
Ayman Bannaga, Ramesh P Arasaradnam, Warwick Medical School, University of Warwick, Coventry CV4 7HL, West Midlands, United Kingdom
Author contributions: Bannaga A was involved in the design, data curation, data analysis, and generating the first draft; Arasaradnam RP supervised the project and edited the draft for intellectual input.
Conflict-of-interest statement: Authors declare no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ayman Bannaga, MBBS, MRCP, Research Fellow, Department of Gastroenterology and Hepatology, University Hospital Coventry and Warwickshire NHS Trust, Clifford Bridge Road, Coventry CV2 2DX, West Midlands, United Kingdom. aymanbannaga@yahoo.com
Received: June 26, 2020 Peer-review started: June 26, 2020 First decision: July 28, 2020 Revised: August 10, 2020 Accepted: August 25, 2020 Article in press: August 25, 2020 Published online: September 7, 2020 Processing time: 69 Days and 15.6 Hours
ARTICLE HIGHLIGHTS
Research background
Neutrophil to lymphocyte ratio (NLR) and albumin bilirubin (ALBI) are emerging prognostic indicators in hepatocellular carcinoma (HCC). This review aimed to evaluate the use of these indicators in published clinical studies over the last 5 years.
Research motivation
HCC staging systems are complex and include many parameters to determine the overall therapeutic goals and prognosis. There is a need for a simple way to prognosticate for these patients. ALBI and NLR are numerical values that can be obtained easily from patient records.
Research objectives
To study the published literature of NLR and ALBI from a clinical point of view.
Research methods
Systematic search over the last 5 years of published literature on NLR and ALBI, and validation of these markers in a retrospective cohort locally in our centre.
Research results
NLR is a generic measure of inflammation in infection, cancer and the critically ill. Raised NLR predicted HCC prognosis and survival. ALBI was better than CTP score in predicting overall survival and liver function in HCC patients. NLR and ALBI can be used in prediction of HCC recurrence after surgery, ablation and chemo/ radioembolisation.
Research conclusions
NLR and ALBI can be used in staging and prognosis of HCC.
Research perspectives
Stakeholders interested in HCC care should consider the use of NLR and ALBI in staging systems for HCC.
